These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1429 related items for PubMed ID: 25484141

  • 1. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
    van Soest RJ, de Morrée ES, Kweldam CF, de Ridder CMA, Wiemer EAC, Mathijssen RHJ, de Wit R, van Weerden WM.
    Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141
    [Abstract] [Full Text] [Related]

  • 2. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
    Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y.
    Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
    [Abstract] [Full Text] [Related]

  • 3. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
    van Soest RJ, van Royen ME, de Morrée ES, Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM.
    Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
    [Abstract] [Full Text] [Related]

  • 4. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.
    JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
    [Abstract] [Full Text] [Related]

  • 5. Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants.
    Shiota M, Dejima T, Yamamoto Y, Takeuchi A, Imada K, Kashiwagi E, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Eto M.
    Cancer Sci; 2018 Oct; 109(10):3224-3234. PubMed ID: 30051622
    [Abstract] [Full Text] [Related]

  • 6. Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation.
    de Morrée E, van Soest R, Aghai A, de Ridder C, de Bruijn P, Ghobadi Moghaddam-Helmantel I, Burger H, Mathijssen R, Wiemer E, de Wit R, van Weerden W.
    Prostate; 2016 Jul; 76(10):927-36. PubMed ID: 26997363
    [Abstract] [Full Text] [Related]

  • 7. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.
    Pezaro CJ, Omlin AG, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D, Dearnaley D, Parker C, de Bono JS, Attard G.
    Eur Urol; 2014 Sep; 66(3):459-65. PubMed ID: 24411987
    [Abstract] [Full Text] [Related]

  • 8. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.
    Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ.
    Eur Urol; 2015 Jan; 67(1):53-60. PubMed ID: 24882673
    [Abstract] [Full Text] [Related]

  • 9. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
    Conteduca V, Jayaram A, Romero-Laorden N, Wetterskog D, Salvi S, Gurioli G, Scarpi E, Castro E, Marin-Aguilera M, Lolli C, Schepisi G, Maugeri A, Wingate A, Farolfi A, Casadio V, Medina A, Puente J, Vidal MJM, Morales-Barrera R, Villa-Guzmán JC, Hernando S, Rodriguez-Vida A, González-Del-Alba A, Mellado B, Gonzalez-Billalabeitia E, Olmos D, Attard G, De Giorgi U.
    Eur Urol; 2019 Mar; 75(3):368-373. PubMed ID: 30773204
    [Abstract] [Full Text] [Related]

  • 10. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.
    van Soest RJ, Nieuweboer AJ, de Morrée ES, Chitu D, Bergman AM, Goey SH, Bos MM, van der Meer N, Hamberg P, de Wit R, Mathijssen RH, Dutch Uro-Oncology Studygroup (DUOS).
    Eur J Cancer; 2015 Nov; 51(17):2562-9. PubMed ID: 26278646
    [Abstract] [Full Text] [Related]

  • 11. Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer.
    Shiota M, Kashiwagi E, Murakami T, Takeuchi A, Imada K, Inokuchi J, Tatsugami K, Eto M.
    Urol Oncol; 2019 Mar; 37(3):180.e19-180.e24. PubMed ID: 30446464
    [Abstract] [Full Text] [Related]

  • 12. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP.
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [Abstract] [Full Text] [Related]

  • 13. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK, Kyprianou N.
    Adv Cancer Res; 2015 Dec; 127():123-58. PubMed ID: 26093899
    [Abstract] [Full Text] [Related]

  • 14. Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
    Nadal R, Zhang Z, Rahman H, Schweizer MT, Denmeade SR, Paller CJ, Carducci MA, Eisenberger MA, Antonarakis ES.
    Prostate; 2014 Nov; 74(15):1560-8. PubMed ID: 25176007
    [Abstract] [Full Text] [Related]

  • 15. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
    Brasso K, Thomsen FB, Schrader AJ, Schmid SC, Lorente D, Retz M, Merseburger AS, von Klot CA, Boegemann M, de Bono J.
    Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579
    [Abstract] [Full Text] [Related]

  • 16. Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.
    Higano CS, Beer TM, Taplin ME, Efstathiou E, Hirmand M, Forer D, Scher HI.
    Eur Urol; 2015 Nov; 68(5):795-801. PubMed ID: 25698064
    [Abstract] [Full Text] [Related]

  • 17. Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
    Zhang T, Dhawan MS, Healy P, George DJ, Harrison MR, Oldan J, Chin B, Armstrong AJ.
    Clin Genitourin Cancer; 2015 Aug; 13(4):392-399. PubMed ID: 25708161
    [Abstract] [Full Text] [Related]

  • 18. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
    Suzman DL, Luber B, Schweizer MT, Nadal R, Antonarakis ES.
    Prostate; 2014 Sep; 74(13):1278-85. PubMed ID: 25053178
    [Abstract] [Full Text] [Related]

  • 19. Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.
    Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS.
    Med Oncol; 2017 Aug 10; 34(9):160. PubMed ID: 28795333
    [Abstract] [Full Text] [Related]

  • 20. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.
    Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann E, Cronauer MV.
    Eur Urol; 2014 Jan 10; 65(1):30-6. PubMed ID: 23849416
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 72.